{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:18:00Z","timestamp":1790957880646,"version":"4.1.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold> Cardiovascular diseases (CVD) remain the leading cause of morbimortality in patients with chronic kidney disease (CKD). The aim of this study was to assess the cardiovascular impact of the pharmacological inhibition of soluble epoxide hydrolase (sEH), which metabolizes the endothelium-derived vasodilatory and anti-inflammatory epoxyeicosatrienoic acids (EETs) to dihydroxyeicosatrienoic acid (DHETs), in the 5\/6 nephrectomy (Nx) mouse model.<\/jats:p><jats:p><jats:bold>Methods and Results:<\/jats:bold> Compared to sham-operated mice, there was decrease in EET-to-DHET ratio 3 months after surgery in vehicle-treated Nx mice but not in mice treated with the sEH inhibitor <jats:italic>t<\/jats:italic>-AUCB. Nx induced an increase in plasma creatinine and in urine albumin-to-creatinine ratio as well as the development of kidney histological lesions, all of which were not modified by <jats:italic>t<\/jats:italic>-AUCB. In addition, <jats:italic>t<\/jats:italic>-AUCB did not oppose Nx-induced blood pressure increase. However, <jats:italic>t-<\/jats:italic>AUCB prevented the development of cardiac hypertrophy and fibrosis induced by Nx, as well as normalized the echocardiographic indices of diastolic and systolic function. Moreover, the reduction in endothelium-dependent flow-mediated dilatation of isolated mesenteric arteries induced by Nx was blunted by <jats:italic>t<\/jats:italic>-AUCB without change in endothelium-independent dilatation to sodium nitroprusside.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Inhibition of sEH reduces the cardiac remodelling, and the diastolic and systolic dysfunctions associated with CKD. These beneficial effects may be mediated by the prevention of endothelial dysfunction, independent from kidney preservation and antihypertensor effect. Thus, inhibition of sEH holds a therapeutic potential in preventing type 4 cardiorenal syndrome.<\/jats:p>","DOI":"10.3389\/fmolb.2020.604042","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T05:43:07Z","timestamp":1615441387000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Soluble Epoxide Hydrolase Inhibition Prevents Experimental Type 4 Cardiorenal Syndrome"],"prefix":"10.3389","volume":"7","author":[{"given":"Mouad","family":"Hamzaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clothilde","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Coquerel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Duflot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery","family":"Brunel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Bellien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Guerrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1073\/pnas.0811022106","article-title":"Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy","volume":"106","author":"Ai","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1053\/j.ajkd.2014.12.016","article-title":"Cardiorenal syndrome and the role of the bone-mineral axis and anemia","volume":"66","author":"Charytan","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1517\/17460441.2014.881354","article-title":"Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases","volume":"9","author":"Duflot","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"key":"B4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12933-019-0843-z","article-title":"Altered bioavailability of epoxyeicosatrienoic acids is associated with conduit artery endothelial dysfunction in type 2 diabetic patients","volume":"18","author":"Duflot","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00216-016-0129-1","article-title":"A sensitive LC-MS\/MS method for the quantification of regioisomers of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids in human plasma during endothelial stimulation","volume":"409","author":"Duflot","year":"2017","journal-title":"Anal. Bioanal. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J. Clin. Invest."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1097\/HJH.0b013e328345ef7b","article-title":"Soluble epoxide hydrolase inhibition prevents coronary endothelial dysfunction in mice with renovascular hypertension","volume":"29","author":"Gao","year":"2011","journal-title":"J. Hypertens."},{"key":"B8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ajpath.2011.03.023","article-title":"Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy","volume":"179","author":"Guerrot","year":"2011","journal-title":"Am. J. Pathol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/s41598-020-58393-w","article-title":"5\/6 nephrectomy induces different renal, cardiac and vascular consequences in 129\/Sv and C57BL\/6JRj mice","volume":"10","author":"Hamzaoui","year":"2020","journal-title":"Sci. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrneph.2012.279","article-title":"Cardiorenal syndrome: Pathophysiology and potential targets for clinical management","volume":"9","author":"Hatamizadeh","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease - a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"key":"B12","doi-asserted-by":"publisher","first-page":"F342","DOI":"10.1152\/ajprenal.00004.2007","article-title":"Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats","volume":"293","author":"Huang","year":"2007","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1161\/hy0202.103788","article-title":"Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension","volume":"39","author":"Imig","year":"2002","journal-title":"Hypertension"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41581-018-0098-z","article-title":"Endothelium structure and function in kidney health and disease","volume":"15","author":"Jourde-Chiche","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1161\/01.HYP.0000153792.29478.1d","article-title":"Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension","volume":"45","author":"Jung","year":"2005","journal-title":"Hypertension"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e11979","DOI":"10.1371\/journal.pone.0011979","article-title":"Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease","volume":"5","author":"Jung","year":"2010","journal-title":"PLoS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1093\/ndt\/gft065","article-title":"Fibroblast growth factor-23: what we know, what we don't know, and what we need to know","volume":"28","author":"Kovesdy","year":"2013","journal-title":"Nephrol. Dial. Transpl."},{"key":"B19","doi-asserted-by":"publisher","first-page":"F1168","DOI":"10.1152\/ajprenal.00606.2015","article-title":"FGF23 from bench to bedside","volume":"310","author":"Kovesdy","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1093\/hmg\/ddl085","article-title":"Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the atherosclerosis risk in communities (ARIC) study","volume":"15","author":"Lee","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1161\/HYPERTENSIONAHA.110.161695","article-title":"Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans","volume":"57","author":"Lee","year":"2011","journal-title":"Hypertension"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3389\/fphar.2018.01551","article-title":"Inhibition of soluble epoxide hydrolase for renal health","volume":"9","author":"Liu","year":"2018","journal-title":"Front Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1073\/pnas.1815746116","article-title":"Inhibition of soluble epoxide hydrolase attenuates a high-fat diet-mediated renal injury by activating PAX2 and AMPK","volume":"116","author":"Luo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B24","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1046\/j.1523-1755.2003.00058.x","article-title":"Model of robust induction of glomerulosclerosis in mice: importance of genetic background","volume":"64","author":"Ma","year":"2003","journal-title":"Kidney Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.yjmcc.2011.11.015","article-title":"Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure","volume":"52","author":"Merabet","year":"2012","journal-title":"J. Mol. Cel. Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1093\/ndt\/gfx332","article-title":"Genetic background influences cardiac phenotype in murine chronic kidney disease","volume":"33","author":"Neuburg","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"B27","doi-asserted-by":"publisher","first-page":"F672","DOI":"10.1152\/ajprenal.00597.2010","article-title":"Effects of cytochrome P-450 metabolites of arachidonic acid on the epithelial sodium channel (ENaC)","volume":"301","author":"Pavlov","year":"2011","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American heart association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"H1020","DOI":"10.1152\/ajpheart.00465.2014","article-title":"Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice","volume":"308","author":"Roche","year":"","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.prostaglandins.2015.04.011","article-title":"Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice","volume":"120","author":"Roche","year":"","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"B31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.prostaglandins.2018.05.008","article-title":"EET enhances renal function in obese mice resulting in restoration of HO-1-Mfn1\/2 signaling, and decrease in hypertension through inhibition of sodium chloride co-transporter","volume":"137","author":"Schragenheim","year":"2018","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"B32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1681\/ASN.2013050465","article-title":"Fibroblast growth factor-23 and cardiovascular events in CKD","volume":"25","author":"Scialla","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/ki.2008.690","article-title":"Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure","volume":"75","author":"Siedlecki","year":"2009","journal-title":"Kidney Int."},{"key":"B34","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ejhf.497","article-title":"Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation","volume":"18","author":"Ter Maaten","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"B35","doi-asserted-by":"publisher","first-page":"F168","DOI":"10.1152\/ajprenal.00129.2012","article-title":"Upregulation of soluble epoxide hydrolase in proximal tubular cells mediated proteinuria-induced renal damage","volume":"304","author":"Wang","year":"2013","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2174\/157016113804547593","article-title":"Soluble epoxide hydrolase inhibitors and cardiovascular diseases","volume":"11","author":"Wang","year":"2013","journal-title":"Curr. Vasc. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"F453","DOI":"10.1152\/ajprenal.00123.2014","article-title":"Cyp2c44 epoxygenase in the collecting duct is essential for the high K+ intake-induced antihypertensive effect","volume":"307","author":"Wang","year":"2014","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"12732","DOI":"10.14814\/phy2.12732","article-title":"Myocardial dysfunction occurs prior to changes in ventricular geometry in mice with chronic kidney disease (CKD)","volume":"4","author":"Winterberg","year":"2016","journal-title":"Physiol. Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"18733","DOI":"10.1073\/pnas.0609158103","article-title":"Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors","volume":"103","author":"Xu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B40","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1161\/01.res.87.11.992","article-title":"Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids","volume":"87","author":"Yu","year":"2000","journal-title":"Circ. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation"},{"key":"B42","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejphar.2010.12.016","article-title":"Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension","volume":"654","author":"Zhang","year":"2011","journal-title":"Eur. J. Pharmacol."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2020.604042\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T05:43:09Z","timestamp":1615441389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2020.604042\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":42,"alternative-id":["10.3389\/fmolb.2020.604042"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2020.604042","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]},"article-number":"604042"}}